Three-month outcomes of treatment with faricimab or aflibercept for neovascular age-related macular degeneration: a propensity score matching study in a Japanese population-Reference-Cited by-同舟云学术

Three-month outcomes of treatment with faricimab or aflibercept for neovascular age-related macular degeneration: a propensity score matching study in a Japanese population

Published:2024-07-29 Issue: Volume: Page:
ISSN:0721-832X
Container-title:Graefe's Archive for Clinical and Experimental Ophthalmology
language:en
Short-container-title:Graefes Arch Clin Exp Ophthalmol

Author:

Fukuda Yosuke,Notomi Shoji^ORCID,Shiose Satomi,Maehara Yusuke,Kiyohara Kohei,Fujiwara Kohta,Hashimoto Sawako,Kano Kumiko,Ishikawa Keijiro,Hisatomi Toshio,Sonoda Koh-Hei

Funder

Japan Society for the Promotion of Science

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00417-024-06582-y.pdf

Reference25 articles.

1. Gragoudas ES, Adamis AP, Cunningham ET Jr., Feinsod M, Guyer DR (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351:2805–2816. https://doi.org/10.1056/NEJMoa042760

2. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S (2006) Ranibizumab versus Verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444. https://doi.org/10.1056/NEJMoa062655

3. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431. https://doi.org/10.1056/NEJMoa054481

4. Ying GS, Huang J, Maguire MG, Jaffe GJ, Grunwald JE, Toth C, Daniel E, Klein M, Pieramici D, Wells J, Martin DF (2013) Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology 120:122–129. https://doi.org/10.1016/j.ophtha.2012.07.042

5. Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, Grunwald JE, Toth CA, Ferris FL 3rd, Fine SL (2016) Five-year outcomes with anti-vascular endothelial growth factor treatment of Neovascular Age-Related Macular Degeneration: the comparison of age-related Macular Degeneration treatments trials. Ophthalmology 123:1751–1761. https://doi.org/10.1016/j.ophtha.2016.03.045